Madhukar Pai
Auto-generated profile, based on publicly available information

Madhukar Pai

School of Population and Global Health, McGill University

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2016 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
MPMadhukar Pai
Madhukar Pai
MBMarcel A. Behr
Marcel A. Behr
DDDavid Dowdy
David Dowdy
KDKeertan Dheda
Keertan Dheda
MDMaziar Divangahi
Maziar Divangahi
MRMario Raviglione
Mario Raviglione

5 August 2008 in Annals of Internal Medicine
Verified
Journal Article
Open access
MPMadhukar Pai
Madhukar Pai
AZAlice Zwerling
Alice Zwerling
DMDick Menzies
Dick Menzies
Tuberculin skin tests (TSTs) and interferon-γ–release assays (IGRAs) are used to detect latent tuberculosis. In an updated meta-analysis, now including 38 studies, Pai and colleagues found that bot... Background: Interferon-γ–release assays (IGRAs) are alternatives to the tuberculin skin test (TST). A recent meta-analysis showed that IGRAs have high specificity, even among populations that have ...

1 April 2019 in The Lancet
Verified
Journal Article
Closed access
JFJennifer J. Furin
Jennifer J. Furin
HCHelen Cox
Helen Cox
MPMadhukar Pai
Madhukar Pai

1 January 2014 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
MPMadhukar Pai
Madhukar Pai
CDClaudia M. Denkinger
Claudia M. Denkinger
SKSandra V. Kik
Sandra V. Kik
MRMolebogeng X. Rangaka
Molebogeng X. Rangaka
AZAlice Zwerling
Alice Zwerling
NBNiaz Banaei
Niaz Banaei
SUMMARY Identification and treatment of latent tuberculosis infection (LTBI) can substantially reduce the risk of developing active disease. However, there is no diagnostic gold standard for LTBI. Two tests are available for identification of LTBI: the tuberculin skin test (TST) and the gamma interferon (IFN-γ) release assay (IGRA). Evidence suggests that both TST and IGRA are acceptable but imperfect tests. They represent indirect markers of Mycobacterium tuberculosis exposure and indicate a cellular immune response to M. tuberculosis. Neither test can accurately differentiate between LTBI and active TB, distinguish reactivation from reinfection, or resolve the various stages within the spectrum of M. tuberculosis infection. Both TST and IGRA have reduced sensitivity in immunocompromised patients and have low predictive value for progression to active TB. To maximize the positive predictive value of existing tests, LTBI screening should be reserved for those who are at sufficiently high risk of progressing to disease. Such high-risk individuals may be identifiable by using multivariable risk prediction models that incorporate test results with risk factors and using serial testing to resolve underlying phenotypes. In the longer term, basic research is necessary to identify highly predictive biomarkers.

6 March 2007 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
DMDick Menzies
Dick Menzies
MPMadhukar Pai
Madhukar Pai
GCGeorge Comstock
George Comstock
Until recently, the tuberculin skin test was the only test for detecting latent tuberculosis (TB) infection, but 2 ex vivo interferon-γ release assays (IGRAs) are now commercially licensed. To estimate sensitivity, specificity, and reproducibility of IGRAs (commercial or research versions of QuantiFERON [QFT] and Elispot) for diagnosing latent TB infection in healthy and immune-suppressed persons. The authors searched MEDLINE and reviewed citations of all original articles and reviews for studies published in English. Studies had evaluated IGRAs using Mycobacterium tuberculosis–specific antigens (RD1 antigens) and overnight (16- to 24-h) incubation times. Reference standards had to be clearly defined without knowledge of test results. Specific criteria for quality assessment were developed for sensitivity, specificity, and reproducibility. When newly diagnosed active TB was used as a surrogate for latent TB infection, sensitivity of all tests was suboptimal, although it was higher with Elispot. No test distinguishes active TB from latent TB. Sensitivity of the tuberculin skin test and IGRAs was similar in persons who were categorized into clinical gradients of exposure. Pooled specificity was 97.7% (95% CI, 96% to 99%) and 92.5% (CI, 86% to 99%) for QFT and for Elispot, respectively. Both assays were more specific than the tuberculin skin test in samples vaccinated with bacille Calmette–Guérin. Elispot was more sensitive than the tuberculin skin test in 3 studies of immune-compromised samples. Discordant tuberculin skin test and IGRA reactions were frequent and largely unexplained, although some may be related to varied definitions of positive test results. Reversion of IGRA results from positive to negative was common in 2 studies in which it was assessed. Most studies used cross-sectional designs with the inherent limitation of no gold standard for latent TB infection, and most involved small samples with a widely varying likelihood of true-positive and false-positive test results. There is insufficient evidence on IGRA performance in children, immune-compromised persons, and the elderly. New IGRAs show considerable promise and have excellent specificity. Additional studies are needed to better define their performance in high-risk populations and in serial testing. Longitudinal studies are needed to define the predictive value of IGRAs.

21 January 2014 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
KSKaren R Steingart
Karen R Steingart
ISIan Schiller
Ian Schiller
DHDavid J Horne
David J Horne
MPMadhukar Pai
Madhukar Pai
CBCatharina C Boehme
Catharina C Boehme
NDNandini Dendukuri
Nandini Dendukuri
Background Accurate and rapid detection of tuberculosis (TB) and drug resistance are critical for improving patient care and decreasing the spread of TB. Xpert® MTB/RIF assay (Xpert) is a rapid, automated test that can detect both TB and rifampicin resistance, within two hours after starting the test, with minimal hands‐on technical time, but is more expensive than conventional smear microscopy. Objectives To assess the diagnostic accuracy of Xpert for pulmonary TB (TB detection), both where Xpert was used as an initial test replacing microscopy, and where Xpert was used as an add‐on test following a negative smear microscopy result. To assess the diagnostic accuracy of Xpert for rifampicin resistance detection where Xpert was used as the initial test, replacing conventional culture‐based drug susceptibility testing. The population of interest was adults suspected of having pulmonary TB or multidrug‐resistant TB (MDR‐TB), with or without HIV infection. Search methods We performed a comprehensive search of the following databases: Cochrane Infectious Diseases Group Specialized Register; MEDLINE; EMBASE; ISI Web of Knowledge; MEDION; LILACS; BIOSIS; and SCOPUS. We also searched the metaRegister of Controlled Trials (mRCT) and the search portal of the WHO International Clinical Trials Registry Platform to identify ongoing trials. We performed searches on 25 September 2011 and we repeated them on 15 December 2011, without language restriction. Selection criteria We included randomized controlled trials, cross‐sectional, and cohort studies that used respiratory specimens to compare Xpert with culture for detecting TB and Xpert with conventional phenotypic drug susceptibility testing for detecting rifampicin resistance. Data collection and analysis For each study, two review authors independently extracted a set of data using a standardized data extraction form. When possible, we extracted data for subgroups by smear and HIV status. We assessed the quality of studies using the QUADAS‐2 tool. We carried out meta‐analyses to estimate the pooled sensitivity and specificity of Xpert separately for TB detection and rifampicin resistance detection using a bivariate random‐effects model. We estimated the median pooled sensitivity and specificity and their 95% credible intervals (CrI). Main results We identified 18 unique studies as eligible for this review, including two multicentre international studies, one with five and the other with six distinct study centres. The majority of studies (55.6%) were performed in low‐income and middle‐income countries. In 17 of the 18 studies, Xpert was performed by trained technicians in reference laboratories. When used as an initial test replacing smear microscopy (15 studies, 7517 participants), Xpert achieved a pooled sensitivity of 88% (95% CrI 83% to 92%) and pooled specificity of 98% (95% CrI 97% to 99%). As an add‐on test following a negative smear microscopy result (14 studies, 5719 participants), Xpert yielded a pooled sensitivity of 67% (95% CrI 58% to 74%) and pooled specificity of 98% (95% CrI 97% to 99%). In clinical subgroups, we found the following accuracy estimates: the pooled sensitivity was 98% (95% CrI 97% to 99%) for smear‐positive, culture‐positive TB and 68% (95% CrI 59% to 75%) for smear‐negative, culture‐positive TB (15 studies); the pooled sensitivity was 80% (95% CrI 67% to 88%) in people living with HIV and 89% (95% CrI 81% to 94%) in people without HIV infection (four studies). For rifampicin resistance detection (11 studies, 2340 participants), Xpert achieved a pooled sensitivity of 94% (95% CrI 87% to 97%) and pooled specificity of 98% (95% CrI 97% to 99%). In a separate analysis, Xpert could distinguish between TB and nontuberculous mycobacteria (NTM) in clinical samples with high accuracy: among 139 specimens with NTM, Xpert was positive in only one specimen that grew NTM. In a hypothetical cohort of 1000 individuals suspected of having rifampicin resistance (a proxy for MDR‐TB), where the prevalence of rifampicin resistance is 30%, we estimated that on average Xpert would wrongly identify 14 patients as being rifampicin resistant. In comparison, where the prevalence of rifampicin resistance is only 2%, we estimated that the number of individuals wrongly identified as rifampicin resistant would increase to 20, an increase of 43%. Authors' conclusions This review shows that Xpert used as an initial diagnostic test for TB detection and rifampicin resistance detection in patients suspected of having TB, MDR‐TB, or HIV‐associated TB is sensitive and specific. Xpert may also be valuable as an add‐on test following microscopy for patients who have previously been found to be smear‐negative. An Xpert result that is positive for rifampicin resistance should be carefully interpreted and take into consideration the risk of MDR‐TB in a given patient and the expected prevalence of MDR‐TB in a given setting. Studies in this review mainly assessed sensitivity and specificity of the test when used in reference laboratories in research investigations. Most studies were performed in high TB burden countries. Ongoing use of Xpert in high TB burden countries will contribute to the evidence base on the diagnostic accuracy and clinical impact of Xpert in routine programmatic and peripheral health care settings, including settings where the test is performed at the point of care.